Bicycle Therapeutics plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BCYC research report →
Range $10 – $10
Price Chart
About the company
Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I/IIa clinical trials.
- CEO
- Kevin Lee
- IPO
- 2019
- Employees
- 288
- HQ
- Cambridge, CAM, GB
Get TickerSpark's AI analysis on BCYC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $203.27M
- P/E
- -1.43
- PEG
- -0.02
- P/S
- 2.43
- P/B
- 0.40
- EV/EBITDA
- 1.88
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -189.50%
- Net Margin
- -169.75%
- ROE
- -26.02%
- ROIC
- -30.20%
Latest fiscal year · YoY change
- Revenue
- $72.59M+105.8%
- Gross Profit
- $72.59M+152.7%
- Op Income
- $-247,718,000
- Net Income
- $-218,960,000-29.5%
- EPS
- $-3.16-8.6%
- OCF Growth
- -51.6%
- FCF Growth
- -51.9%
- 52W High
- $7.83
- 52W Low
- $2.85
- 50D MA
- $3.63
- 200D MA
- $4.34
- Beta
- 1.60
- RSI (14)
- 33
- Avg Volume
- 436.24K
No earnings-call transcripts are available for BCYC yet.
- Free Float
- 88.6%
- Shares Outstanding
- 70.09M
- Float Shares
- 62.09M
of shares held by institutions
112 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Baker Bros. Advisors LP | 10.89M | 0 |
| Armistice Capital, LLC | 3.47M | ▲ 74.00K |
| Fcpm Iii Services B.V. | 3.47M | 0 |
| Long Focus Capital Management, LLC | 3.31M | 0 |
| Acadian Asset Management LLC | 1.99M | ▲ 25.07K |
| Gsk PLC | 1.53M | 0 |
| Renaissance Technologies LLC | 1.51M | ▼ 23.96K |
| Two Sigma Investments, LP | 1.12M | ▲ 684.14K |
| Qube Research & Technologies Ltd | 840.36K | ▲ 64.80K |
| Marshall Wace, Llp | 835.86K | ▲ 37.92K |
| Morgan Stanley | 640.52K | ▼ 26.75K |
| Schroder Investment Management Group | 615.83K | 0 |
Held by 24 ETFs
Biggest fund positions in BCYC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 5, 26 | Perry Jennifer Scott | sell | 30 |
| Oct 5, 26 | Perry Jennifer Scott | sell | 326 |
| Oct 2, 26 | Swanton Robert Charles | sell | 3,431 |
| Oct 2, 26 | Skynner Michael | sell | 1,942 |
| Oct 5, 26 | Skynner Michael | sell | 503 |
| Oct 2, 26 | Hannay Michael Charles Ferguson | sell | 1,572 |
| Oct 5, 26 | Hannay Michael Charles Ferguson | sell | 242 |
| Oct 2, 26 | Perry Jennifer Scott | sell | 1,094 |
| Oct 5, 26 | Perry Jennifer Scott | sell | 80 |
| Oct 5, 26 | Perry Jennifer Scott | sell | 326 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BCYC coverage
Recent articles, reports, and earnings notes.
No research on BCYC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BCYC report →Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results
businesswire.com · Oct 29
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Stock Now Rated “Hold” by Wall Street Brokerages
defenseworld.net · Oct 22
Head-To-Head Survey: Celldex Therapeutics (NASDAQ:CLDX) & Bicycle Therapeutics (NASDAQ:BCYC)
defenseworld.net · Sep 21
Financial Review: Intellia Therapeutics (NASDAQ:NTLA) vs. Bicycle Therapeutics (NASDAQ:BCYC)
defenseworld.net · Sep 21
Visa Inks $2.4 Billion Deal to Acquire Fraud Prevention Firm BioCatch
pymnts.com · Aug 3
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
businesswire.com · Jul 30
Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
businesswire.com · May 21
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
businesswire.com · Apr 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.